The RNA binding protein Musashi1 regulates apoptosis, gene expression and stress granule formation in urothelial carcinoma cells

Parvaneh Nikpour a, b, Modjtaba Emadi Baygi c, Christine Steinhoff d, Christiane Hader e, Anna C. Luca f, Seyed J. Mowla a, Wolfgang A. Schulz e, *

a Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
b Department of Genetics and Molecular Biology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
c Department of Genetics, Faculty of Basic Sciences, Shahrekord University, Shahrekord, Iran
d Max Planck Institute for Molecular Genetics, Department of Computational Molecular Biology, Berlin, Germany
e Department of Urology, Heinrich Heine University, Düsseldorf, Germany
f Department of Surgery, Heinrich Heine University, Düsseldorf, Germany

Received: January 14, 2010; Accepted: April 17, 2010

Abstract

The RNA-binding protein Musashi1 (MSI1) is a marker of progenitor cells in the nervous system functioning as a translational repressor. We detected MSI1 mRNA in several bladder carcinoma cell lines, but not in cultured normal uroepithelial cells, whereas the paralogous MSI2 gene was broadly expressed. Knockdown of MSI1 expression by siRNA induced apoptosis and a severe decline in cell numbers in 5637 bladder carcinoma cells. Microarray analysis of gene expression changes after MSI1 knockdown significantly up-regulated 735 genes, but down-regulated only 31. Up-regulated mRNAs contained a highly significantly greater number and density of Musashi binding sites. Therefore, a much larger set of mRNAs may be regulated by Musashi1, which may affect not only their translation, but also their turnover. The study confirmed p21CIP1 and Numb proteins as targets of Musashi1, suggesting additionally p27KIP1 in cell-cycle regulation and Jagged-1 in Notch signalling. A significant number of up-regulated genes encoded components of stress granules (SGs), an organelle involved in translational regulation and mRNA turnover, and impacting on apoptosis. Accordingly, heat shock induced SG formation was augmented by Musashi1 down-regulation. Our data show that ectopic MSI1 expression may contribute to tumorigenesis in selected bladder cancers through multiple mechanisms and reveal a previously unrecognized function of Musashi1 in the regulation of SG formation.

Keywords: Musashi gene family • bladder cancer • apoptosis • stress granules • translational regulation • gene expression microarray

Introduction

The Musashi family is an evolutionarily conserved group of RNA-binding proteins [1, 2] which in mammals comprises the Musashi1 and Musashi2 proteins, encoded by the MSI1 and MSI2 genes, [3, 4], resembling each other in their RNA-binding domains [4]. Musashi1 is mainly expressed in central nervous system (CNS) stem cells and neural progenitor cells [2], but also in stem cell-enriched regions of murine and human intestinal crypts and stomach pits [5–7] and in epithelial progenitors in gastric mucosa, gut, mammary glands, epidermis and hair follicles [2, 6, 8, 9]. In contrast, Musashi2 is expressed in a wide variety of tissues, although its expression in the CNS is cell type specific and developmentally regulated [4].

Musashi1 functions as a translational repressor through sequence-specific interaction with the 3’-untranslated region (UTR) of various target mRNAs [10]. The best-established targets of Musashi1 are regulators of Notch signalling and the cell cycle such as Numb [10], an evolutionary conserved antagonist of the Notch pathway. Therefore, Musashi1 is thought to activate Notch signalling required for the self-renewal of mammalian neural stem
cells. Accordingly, in NIH-3T3 cells, Musashi1 induces transactivation of the Notch target gene, Hes1 [2, 10]. Moreover, Musashi1 has been reported to repress translation of the cyclin-dependent kinase inhibitor p21CIP1 [11], which is necessary for commitment has been reported to repress translation of the cyclin-dependent cers through several mechanisms.

Musashi1 expression has also been reported in a variety of tumour cells, including glioblastoma, retinoblastoma, endometrial carcinoma, colorectal carcinoma and hepatoma cell lines [14–20]. The function of Musashi in tumour cells, however, is not well understood. Presumably, it may contribute to the maintenance of the self-renewal capacity of tumour (stem) cells by enhancing Notch pathway activity and preventing p21CIP1-induced cell-cycle arrest. In this study, we detected expression of MSI1 genes in several bladder carcinoma cell lines, but not proliferating normal uroepithelial cells. Using an RNAi strategy, we observed that Musashi1 down-regulation decreased tumour cell proliferation by promoting cell death. A microarray analysis revealed expected and potential novel Musashis1 targets in Notch signalling and cell-cycle regulation and an unexpected effect on formation of SGs after heat-shock treatment. Our study suggests that ectopic expression of Musashi1 contributes to carcinogenesis in some urothelial cancers through several mechanisms.

Methods and materials

Cell lines, cell culture, siRNA transfection and heat-shock treatment

Bladder carcinoma cell lines and normal uroepithelial cells were cultured as described [21]. For heat-shock treatment, cells on cover slips were floated in the culture dish in a pan of water at 44°C for 20 min. and immediately thereafter fixed with paraformaldehyde/methanol.

Double-stranded, short (21-mer) interfering RNA (siRNA) corresponding to MSI1 mRNA and a control non-targeting siRNA (IR-siRNA) with the following sense and antisense sequences were purchased from MWG (Ebersberg, Germany):

MSI1 sense/antisense
GGGAAAGUGUGUGAAUUUdTdT/ AAUUUCACACAUUUCUCcdTdT
Irrelevant: sense/antisense
CUAGUUGCAUGUAUUCGudTdT/ AGCGGAAUACGUAUUAUGdTdT

Cells were transfected with 25 μM siRNA at 30–50% confluency using Lipofectamine™ RNAiMAX following the recommendations of the manufacturer (Invitrogen, Karlsruhe, Germany). For replication experiments, MSI1 siRNA GL-#11338–00 and non-targeting control D#-001810–10-OS (Dharmacon, Schwerte, Germany) were used at 10 μM with the same transfection reagent. Unless otherwise indicated, all assays were performed 3 days later.

RNA extraction

Total RNA was isolated from sub-confluant cell cultures and cell lines using Qiazol reagent (Qiagen, Hilden, Germany) and purified via RNeasy columns (Qiagen). cDNA synthesis was performed with SuperScriptII reverse transcriptase (Promega, Mannheim, Germany) with oligo-dT primers as described [22].

DNA extraction

High molecular weight genomic DNA from cell lines was isolated using the blood and cell culture DNA kit (Qiagen) with additional proteinase K treatment.

Methylation analysis

Bisulphite treatment of 1 μg of DNA from each sample was performed with the EZ DNA Methylation-Gold Kit™ (Zymo Research Corp, USA, Freiburg, Germany) yielding 50 μl converted DNA from each sample. For bisulphite sequencing, PCR of the MSI1 promoter was performed with specific primers (For: GTAGGGATTGAGAGGGAAGA and Rev: AACAAACCATACTACCCCCT), in a volume of 50 μl containing 150 μM deoxyribonucleotide triphosphates (dNTPs), 0.3 μM of each primer, 1× PCR buffer (Qiagen), 1.0 U Hot Star Taq polymerase (Qiagen) and 2 μl of converted DNA. The initial denaturing step at 94°C for 15 min. was followed by 37 cycles each consisting of a denaturing step at 95°C for 30 sec., primer annealing at 59°C for 30 sec. and a 45 sec. elongation step at 72°C. The final 72°C period was extended to 10 min. Subsequently, PCR products were verified by agarose gel electrophoresis and subcloned into the pCR4-TOPO vector (Invitrogen, Groningen, Netherlands). At least four clones for each sample were sequenced by standard methods, and the number of clones analysed was increased to eight, if heterogeneous methylation patterns were detected.

Cell proliferation assay

Viable cells were quantified using the Cell Titer-Glo Luminescent Cell Viability Assay (Promega) according to the manufacturer’s instructions. Results were based on four different experiments.

Cell cycle analysis

For flow cytometry analysis, cells were harvested by trypsinization 72 hrs after transfection, washed with PBS, then stained with 50 μg/ml propidium iodide solution containing 0.1% Triton X-100 and sodium citrate as described [23] and were analysed for cell-cycle distributions using a FACS Calibur instrument (Becton Dickinson, Heidelberg, Germany). Cell-cycle profiles were analysed using WinMDI version 2.8 software.

Caspase assays

Caspase-3 and -7 activities were measured in quadruplicate with the Caspase-Glo 3/7 reagents (Promega).

RT-PCR

Real-time RT-PCR assays were performed with the LightCycler II apparatus (Roche, Mannheim, Germany). Real-time RT-PCR for ADAM19 [ADAM
metalloproteinase domain 19 (NCBI GeneID: 8728)), APAP1 [amyloid beta (A4) precursor protein (NCBI GeneID: 351)], BINP3 [BCL2/adenovirus E1B 19kDa interacting protein 3 (NCBI GeneID: 664)], CCNL1 [cyclin L1 (NCBI GeneID: 57018)], CDKN1B [cyclin-dependent kinase inhibitor 1B (p27, Kip1) (NCBI GeneID: 10271)], HEY1 [hairy/enhancer-of-split related with YRPW motif 1 (NCBI GeneID: 23462)], HIP1 [huntingtin interacting protein 1 (NCBI GeneID: 3092)], ITGB1 [integrin, beta 1 (NCBI GeneID: 3688)], RARAS [related RAS viral (r-ras) oncogene homolog (NCBI GeneID: 6237)], TIA1 [TIA1 cytotoxic granule-associated RNA binding protein (NCBI GeneID: 7072)] and TBP [TATA box binding protein (NCBI GeneID: 6908)].

mRNAs was performed with specific Quantitect primer assays (Qiagen) with the QuantiTect SYBR Green PCR Kit (Qiagen). Real-time RT-PCR for JAG1 [jagged 1 (NCBI GeneID: 182)] was performed with TaqMan assays in the GeneAmp 5700 Sequence Detection System (Applied Biosystems, Darmstadt, Germany). Real-time RT-PCR for MSI1 [musashi homolog 1 (NCBI GeneID: 4440)], MSI2 [musashi homolog 2 (NCBI GeneID: 125450)], CDKN1A [cyclin-dependent kinase inhibitor 1A (p21, Cip1) (NCBI GeneID: 1026)], NUMB [numb homolog (Drosophila) (NCBI GeneID: 8560)], HES1 [hairy and enhancer of split 1 (NCBI GeneID: 3280)], SRYPR2 [sprouty homolog 2 (NCBI GeneID: 10253)] and GADPH [glyceraldehyde-3-phosphate dehydrogenase (NCBI GeneID: 2597)] mRNAs was done using specific primers (Table S1) with the LightCycler-FastStart DNA Master PLUS SYBR Green PCR Kit (Roche) or the QuantiTect SYBR Green PCR Kit (Qiagen).

Values are expressed as mean ± S.E.M.

### Microarray analysis and evaluation

Linear T7 polymerase-based amplification of total RNA from the three independent irrelevant (IR)-treated and MSI1-treated 5637 cell cultures was performed essentially as previously described [24]. RNA samples were then hybridized in duplicate to HG-U133A GeneChips (Affymetrix, Santa Cruz, Heidelberg, Germany) with the QuantiTect SYBR Green PCR Kit (Qiagen). Values are expressed as mean ± S.E.M.

Differential gene expression was determined by permutation test. All normalized expression values were used for further analysis. minimal signal intensity was subtracted, a probe-specific background correction was not applied. Probe-set intensities of each probe set were summarized by applying the Tukey’s median polish method [29] after normalization. Normalized expression values were used for further analysis.

To determine differential expression, the multitest package was used [26]. Differential gene expression was determined by permutation test. All tests were adjusted for multiple testing applying Benjamini–Hochberg adjustments [30]. P-values of <0.05 were considered to indicate statistical significance. Original designations by the array supplier for significant genes were annotated using the ensembl (www.ensembl.org) and the information hyperlinked over proteins (iHOP) [31] databases. Gene ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed with the WebGestalt software [32].

### Western blotting

Cells were lysed in RIPA buffer containing 1% triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate and complete protease inhibitor cocktail. Lysates containing the equivalent of 30 µg protein per lane were electrophoresed using SDS-PAGE (12% polyacrylamide gel) and were blotted on Immobilon-P membranes (Millipore, Hamburg, Germany). Blots were blocked for 1 hr with 5% milk powder in phosphate-buffered saline tween (PBST) or 3% bovine serum albumin and 1% milk powder in tris-buffered saline (TBS). They were then probed with polyclonal antibodies against Musashi1 (1:500; Novus, Hidenhausen, Germany), p21CIP1 (1:500; BD Biosciences, Heidelberg, Germany), m-Numb (1:500, Santa Cruz, Heidelberg, Germany), Jagged-1 (1:1000; Santa Cruz), p27Kip1 (1:1000, Santa Cruz) or α-Tubulin (1:10,000, Sigma-Aldrich, Munich, Germany) as a loading control and subsequently with the horseradish peroxidase conjugated appropriate secondary antibodies (1:5000 or 1:100,000 with the enhanced kit). Staining was visualized using an (advanced) ECL chemiluminescence kit (Amersham Biosciences, Freiburg, Germany) or Immun-Star WesternC Kit (Biorad, Munich, Germany).

### Immunofluorescence detection of stress granules

Fixed cells were incubated for 1 hr in PBS containing 4% bovine serum albumin and 0.05% saponine and subsequently stained overnight with anti-TIA-1 (1:200, Santa Cruz) antibody. Thereafter, cells were washed 2× in PBS and labelled with secondary antibody (1:500, Alexa 488-coupled anti-goat IgG [Invitrogen]). DNA was detected using DAPI (4,6-diamidino-2-phenylindole, 1 mg/ml; Sigma-Aldrich). Stainings were evaluated with a Nikon Eclipse 200/400 microscope (Nikon, Düsseldorf, Germany) and NIS Elements D2–30 software. Percentages of cells harbouring ≥5 SGs were determined by analysis of >4 fields in two independent experiments for a minimum of each 500 cells counted.

### Further statistical analyses

Unless indicated otherwise, Student’s t-test was used for statistical analyses. All experiments were replicated three or four times.

### Results

#### Expression and siRNA-mediated down-regulation of MSI1 in urothelial carcinoma cells

According to quantitative RT-PCR, 8 of 15 bladder carcinoma cell lines displayed MSI1 expression, in particular 639v and 5637 (Fig. 1A). No expression of MSI1 was observed in any of several examined primary cultures of normal uroepithelial cells. In contrast, expression of MSI2 was observed in all examined cell lines as well as normal uroepithelial cells (Fig. 1B).

The mechanisms responsible for cell type specific expression of MSI1 are unknown. Because developmental genes are often silenced by DNA methylation in non-expressing cells, we investigated a region in the proximal MSI1 promoter by bisulphite sequencing. Four bladder carcinoma cell lines were compared to two independent primary cultures of normal uroepithelial cells. The 55 CpG sites located close to the transcriptional start site were
Figure 1: Expression of MSI1 and MSI2 in bladder cancer cell lines and normal urothelial cells. Relative gene expression of MSI1 to GAPDH (A) and MSI2 to GAPDH (B) as determined by quantitative RT-PCR in bladder cancer cell lines (black columns) and several independent cultures of normal uroepithelial cells (NUECs, white columns). Values shown represent the mean ± S.E.M.
found completely unmethylated in normal uroepithelial cells, whereas SD and 5637 cells both exhibited partial methylation (Fig. S1), despite their very different expression levels of MSI1 mRNA (Fig. 1A). These results suggest that DNA methylation is not a major factor in the silencing of MSI1 in normal urothelial cells or cancer cell lines.

To investigate the function of Musashi1 by RNAi, we selected the 5637 and 639v cell lines, with high MSI1 and low MSI2 expression. Analysis by quantitative RT-PCR demonstrated that application of MSI1-siRNA for 3 days resulted in a dramatic reduction in MSI1 mRNA expression by 94% and 83%, respectively, in 5637 and 639v cells compared to cells treated with an IR-siRNA (Fig. 2A). Strong down-regulation was already apparent after 24 hrs (data not shown). As shown by Western blotting, the reduction in MSI1 mRNA was followed by a similar reduction at the protein level in MSI1-siRNA transfected 5637 and 639v cells (Fig. 2C). Down-regulation of MSI1 was accompanied by a moderate up-regulation of MSI2 mRNA expression by 50% and 45%, respectively, in 5637 and 639v cells compared to cells treated with a control siRNA.

Effects of Musashi1 knockdown on cell proliferation and apoptosis

Three days after transfection, cell numbers, as measured by total ATP amounts, were diminished by 83% in MSI1-siRNA treated 5637 cells compared to cells treated with IR-siRNA (3.3 ± 0.5 × 10^3 versus 19.0 ± 1.4 × 10^3, P < 0.05). After 1 and 2 days, ATP amounts were reduced by 30% and 40%, respectively. A weaker decrease, by 24%, was observed upon MSI1 down-regulation in 639v cells (14.2 ± 1.1 × 10^3 versus 18.7 ± 1.2 × 10^3). No significant change was elicited by treating normal uroepithelial cells, which lack MSI1 mRNA expression, with MSI1 siRNA (33.4 ± 0.7 × 10^4 versus 36.4 ± 1.1 × 10^4).

In flow cytometry analysis in 5637 cells treated with MSI1- and IR-siRNAs, the fraction of cells appearing in 'sub-G1', indicative of apoptosis, increased significantly (P < 0.05) almost 2-fold from 4.6 ± 0.1% in MSI1-siRNA compared to IR-treated 5637 cells (Fig. 3A). Treatment of 639v cells with MSI1-siRNA showed a much weaker and non-significant effect (Fig. 3B). Moreover, MSI1-siRNA treatment
Fig. 3 Effect of MSI1 knockdown on cell-cycle distribution in bladder cancer cell lines. Cell-cycle distribution of 5637 (A) and 639v (B) cell lines after MSI1-siRNA treatment. The upper panels show the sub-G1 population of cells as depicted by the FL3 filter of the FACS instrument and the lower panels show the distribution and respective percentages of cells in the G0/G1, S and G2/M phases.
Effects of Musashi1 knockdown on gene expression

To examine how down-regulation of MSI1 influenced gene expression, we performed a microarray experiment using HG-U133A oligonucleotide arrays. Of the approximately 13,000 genes represented on the array, 735 genes were significantly up-regulated at least 2-fold, but only 31 were down-regulated in a statistically significant manner after treatment of 5637 cells with MSI1-siRNA compared to IR-siRNA (Table S2).

Among the genes down-regulated by MSI1 siRNA treatment, several typically expressed in keratinocytes were conspicuous. Accordingly, the by far most significantly enriched gene ontology group among the 31 down-regulated genes was ‘epidermis development’ (Fisher’s exact test: P = 7 x 10^{-7}).

Among the much more numerous genes up-regulated after Musashi1 knockdown, a number of gene ontology (GO) groups were overrepresented (Table 1). According to this analysis, genes regulated by Musashi1 are involved in endoplasmic reticulum (ER) and Golgi function, protein secretion and protein ubiquitination, in signalling across the cell membrane through adhesion molecules and tyrosine kinase receptors, and in the regulation of cell proliferation. Notably, the GO groups ‘positive regulation of cell proliferation’, ‘negative regulation of cell proliferation’ as well as ‘epithelial cell proliferation’ were all significantly overrepresented. Unexpectedly in view of the overall effect of MSI1 knockdown on 5637 cells, a significant number of genes involved in ‘negative regulation of apoptosis’ were up-regulated. However, some pro-apoptotic genes also became strongly up-regulated, in particular BNIP and BNIP3L [33], by 3.2-fold and 4.7-fold, respectively.

Up-regulation of several cell cycle and cell death-related genes after MSI1 depletion was confirmed by quantitative RT-PCR for CDKN1A/p21, CDKN1B/p27, BNIP3, SPRY2 and HPP1 transcripts (Fig. 4A). Likewise, according to Western blotting, p21^{CIP1} and p27^{kip1} protein levels increased after MSI1 down-regulation in 5637 cells, but not in 639v cells (Fig. 4B). Intriguingly, 639v cells did not form SGs under either condition.

Bioinformatic analysis of Musashi1 binding sites in regulated mRNAs

We finally compared several relevant mRNA structural parameters between the 31 down-regulated and the 31 most strongly up-regulated genes after MSI1 knockdown, namely the transcript length, the length of the 3’-UTR, the relative length of the 3’-UTR in relation to the overall transcript length, the number of MSI1 consensus binding sites ((G/A)UAGU [n = 1–3]) per 3’-UTR of each transcript and the number of Musashi1 binding sites per relative length of 3’-UTR. Interestingly, every parameter showed a highly significant difference between up-regulated and down-regulated genes (Table 3).
Discussion

Musashi1 is considered to be a key molecule for stemness in various tissues and its expression has also been linked to increased cell proliferation in breast and intestinal cancers [40]. Musashi1 might exert an oncogenic function through its ability to repress translation of specifically bound mRNAs, including those for regulators of Notch signalling and the cell cycle like Numb and p21CIP1 [10, 11]. However, the oncogenic functions of Musashi1 are poorly understood to date.

In the present study, we observed expression of MSI1 in a subset of bladder cancer cell lines, but never in normal uroepithelial cells, even though these proliferate robustly in culture. Therefore, as observed in other cancer types, some urothelial cancers may ectopically express MSI1. The major effect of siRNA-mediated down-regulation in two bladder cancer cell lines was increased apoptosis, which was considerably more pronounced in the 5637 cell line, with only a slight increase in the G1/G0 fraction. The fact that no significant change in cell viability was observed in MSI1-siRNA treated normal uroepithelial cells excludes off-target effects of the treatment. An elevated apoptotic rate following MSI1 suppression was also observed in some previous studies on other cell types [17, 41], but not generally [11, 42]. Moreover, overexpression of Msi1 stimulated proliferation and increased S and G2/M

Table 1 Gene ontology (GO) groups most overrepresented after MSI1 knockdown in 5637 cells

| GO group name                                      | GO group level* | No. of genes observed | No. of genes expected | P-value** |
|---------------------------------------------------|----------------|-----------------------|-----------------------|-----------|
| Golgi vesicle transport                           | 8              | 19                    | 5.8                   | 0.000027  |
| Enzyme-linked receptor protein signalling pathway | 6              | 26                    | 10.9                  | 0.000115  |
| ER to Golgi vesicle-mediated transport            | 9              | 14                    | 4.1                   | 0.000209  |
| Regulation of cell proliferation                  | 5              | 35                    | 17.6                  | 0.000238  |
| Vesicle-mediated transport                        | 5              | 36                    | 19.4                  | 0.000619  |
| Cell organization and biogenesis                  | 4              | 107                   | 77.9                  | 0.000648  |
| Secretory pathway                                 | 5              | 23                    | 10.7                  | 0.00102   |
| Cell motility                                     | 4              | 27                    | 13.5                  | 0.00105   |
| Cellular localization                             | 5              | 49                    | 30.4                  | 0.00128   |
| Cell migration                                    | 5              | 15                    | 5.8                   | 0.00162   |
| Establishment of cellular localization            | 6              | 48                    | 30.1                  | 0.00170   |
| Intracellular transport                           | 7              | 47                    | 29.7                  | 0.00226   |
| Small GTPase-mediated signal transduction         | 6              | 32                    | 15.9                  | 0.00336   |
| Negative regulation of programmed cell death      | 7              | 18                    | 8.4                   | 0.00372   |
| Epithelial cell proliferation                     | 5              | 4                     | 0.5                   | 0.00380   |
| Protein ubiquitination                            | 9              | 9                     | 2.9                   | 0.00455   |
| Negative regulation of cell proliferation         | 6              | 19                    | 9.3                   | 0.00460   |
| Positive regulation of cell proliferation         | 6              | 17                    | 8.0                   | 0.00505   |
| Negative regulation of cellular physiological process | 5             | 55                    | 38.1                  | 0.00582   |
| Transmembrane receptor protein serine/threonine kinase signalling pathway | 7          | 8                     | 2.5                   | 0.00609   |
| Protein modification by small protein conjugation  | 8              | 9                     | 3.1                   | 0.00671   |
| Negative regulation of apoptosis                  | 8              | 17                    | 8.3                   | 0.00679   |
| Transforming growth factor β receptor signalling pathway | 8         | 7                     | 2.0                   | 0.00692   |
| Transmembrane receptor protein tyrosine kinase signalling pathway | 7          | 16                    | 7.7                   | 0.00740   |
| Positive regulation of epithelial cell proliferation | 7          | 3                     | 0.3                   | 0.00750   |
| Positive regulation of cellular process           | 4              | 48                    | 32.9                  | 0.00846   |
| Cell proliferation                                | 4              | 46                    | 31.5                  | 0.00954   |

*Only GO groups at level >3 were considered.
**Fisher’s exact test.
fractions in a mouse mammary epithelial cell line [43] and human embryonic kidney cells [11]. In the human colon cancer cell line HCT116 too, knockdown of MSI1 decreased the fraction of actively cycling cells [17]. Considering these results together, it seems that effects of MSI1 on cell-cycle distribution occur in a cell-context dependent manner. An explanation for the various outcomes is suggested by the result of our microarray analysis that MSI1 knockdown increased the expression of both proliferation inhibitory and stimulatory genes in 5637 (Table 1). The ultimate effect of MSI1 may therefore depend on how the balance between these genes turns out in a particular cell type. In a similar fashion, both anti-apoptotic and pro-apoptotic genes turned out to be influenced by MSI1 in our analysis. Although a significant number of genes involved in negative regulation of apoptosis were up-regulated after MSI1-siRNA treatment, two pro-apoptotic genes, BNIP and BNIP3L, encoding NIP3 and NIX (NIP-like protein X) [33] became induced too. They are possible candidates for mediating apoptosis in 5637 cells in response to MSI1 knockdown. In addition, although p21\textsuperscript{CIP1} and p27\textsuperscript{KIP1}, which were up-regulated under that condition are often anti-apoptotic, they can promote apoptosis under certain conditions [44, 45], presumably because apoptosis frequently occurs in cells in the G1 phase of the cell cycle [46, 47], and arrest in late G1 or S phase mediated by the cell-cycle inhibitors can then accelerate or potentiate apoptosis [48]. However, the mechanism of apoptosis in this case could be more complex, as suggested below.

In accordance with previous work [10, 11], we observed up-regulation of both Numb and p21\textsuperscript{CIP1} proteins after MSI1 down-regulation in 5637 cells. Our findings, however, may extend present knowledge in several respects (summarized in Fig. 8).
Table 2  SG-related proteins as cited in Ref. [39] and their expression changes after MSI1 knockdown

| Protein     | Gene symbol | Related gene(s) | Expression changes after MSI1 knockdown | Fold change | Adjusted P-value |
|-------------|-------------|-----------------|----------------------------------------|-------------|------------------|
| Ago2        | EIF2C2      |                 | No change                             |             |                  |
| APOBEC3G    | APOBEC3G    |                 | Up-regulated                          | 2.41        | 0.018            |
| Ataxin-2    | ATXN2       |                 | No change                             |             |                  |
| Caprin-1    | GPIAP1      |                 | Not present                           |             |                  |
| CPEB        | CPEB1       |                 | No change                             |             |                  |
| DISC1       | DISC1       |                 | No change                             |             |                  |
| elf3        |             | EIF3A           | Up-regulated                          | 2.83        | 0.028            |
| elf4E       | elf4E       |                 | Up-regulated                          | 2.45        | 0.028            |
| elf4G       | EIF4G1      |                 | Up-regulated                          | 1.63        | 0.035            |
| FAST        | FASTK       | FASTKD3         | Up-regulated                          | 1.62        | 0.046            |
| FMRP        | FMR1        |                 | No change                             |             |                  |
| FXR1        | FXR1        |                 | Up-regulated                          | 2.60        | 0.018            |
| FBP         | FUBP1       | FUBP3           | Up-regulated                          | 2.94        | 0.028            |
| KSRP        | KHSRP       |                 | No change                             |             |                  |
| G3BP        | G3BP        | G3BP2           | Up-regulated                          | 2.37        | 0.035            |
| HuR         | ELAVL1      |                 | No change                             |             |                  |
| IP5K        | IPPK        |                 | No change                             |             |                  |
| Lin28       | LIN28       |                 | No change                             |             |                  |
| LINE 1 ORF1p | LRE1       |                 | Not present                           |             |                  |
| MLNS1       | CASC3       |                 | No change                             |             |                  |
| PABP-1      | PABPC1      |                 | No change                             |             |                  |
| RCK (p54)   | DDX6        |                 | No change                             |             |                  |
| Plakophilin | PKP1        |                 | No change                             |             |                  |
| PMR1        | ATP2C1      |                 | Up-regulated                          | 1.87        | 0.035            |
| Pumilio 2   | PUM2        |                 | Up-regulated                          | 1.66        | 0.018            |
| Rap 55      | LSM14A      |                 | Up-regulated                          | 3.01        | 0.018            |
| Rpb 4       | POLR2D      | POLR2K          | Up-regulated                          | 1.98        | 0.028            |
| SRC3        | NCOA3       |                 | No change                             |             |                  |
| Staufen     | STAU1       |                 | No change                             |             |                  |
| SMN         | SMN1        |                 | No change                             |             |                  |
| TIA-1       | TIA1        |                 | Up-regulated                          | 3.07        | 0.018            |
| TIAR        | TIAL1       |                 | No change                             |             |                  |
| TRAF2       | TRAF2       |                 | No change                             |             |                  |
| TTP         | ZFP36       |                 | No change                             |             |                  |
| BRF1        | ZFP36L1     |                 | Up-regulated                          | 1.87        | 0.028            |
| YB-1        | YBX1        |                 | No change                             |             |                  |
| ZBP-1       | ZBP1        |                 | No change                             |             |                  |
First, we observed that not only the levels of Numb and p21CIP1 proteins, but also the levels of their corresponding mRNAs were elevated, suggesting that translational inhibition by Musashi1 also affects the turnover of the respective mRNAs. A plausible explanation for this effect is the recent finding that Musashi1 elicits the transport of its target mRNAs to particles in the cell that sort RNAs for reuse, storage or degradation [13]. Interestingly, TIA-1 has a similarly dual role as a suppressor of translation as well as a regulator of the decay of selected mRNAs [38].

Second, our siRNA study, in accordance with another investigation employing MSI1 overexpression [43] suggests that the range of Musashi1 targets may be much wider than hitherto recognized. Although it is not trivial to distinguish between direct effects of Musashi1 on mRNAs and effects elicited by secondary changes in transcription, two arguments support the idea that a substantial fraction of the genes identified as up-regulated in the microarray study (Table S2) are direct Musashi1 targets. A comparison of the RNA structures of the most strongly up-regulated and down-regulated genes showed that the up-regulated mRNAs had significantly longer 3′-UTRs and significantly more predicted binding sites overall and per unit of length, for Musashi1 protein. Moreover, secondary transcriptional changes would be expected to result in a similar number of up-regulated and down-regulated genes, whereas we observed a huge excess of up-regulated mRNAs, as one might expect after removal of a protein promoting mRNA turnover.

Third, our study suggests that MSI1 effects on cell-cycle regulation and Notch signalling may be mediated not only by p21CIP1 and Numb, respectively. Although we did not find a significant overall enrichment of cell cycle regulatory or Notch pathway

Fig. 6 Expression of genes related to RNA turnover in MSI1-siRNA treated 5637 cells. Expression of CCNL1, TIA1, RRAS and APP1 relative to TBP in the bladder cancer cell line 5637 after suppression of MSI1 as determined by quantitative RT-PCR. In all cases, the relative expression of each gene in IR-siRNA treated controls was adjusted to 100. Statistically significant differences (P < 0.05) are marked by asterisks.

Fig. 7 Effect of MSI1 depletion on formation of SGs in bladder cancer cell lines 5637 and 639v. (A) SGs are visualized as distinctive irregularly shaped speckles after immunocytochemical staining for TIA-1. Note the absence of SGs under either condition in 639v cells. (B) Number of 5637 cells with >5 SGs under the indicated conditions. Statistically significant differences are indicated.
genes in the bioinformatic analysis of the microarray results, several additional genes in these regulatory systems were clearly influenced by MSI1 knockdown. In cell-cycle regulation, at least p27kip1 was up-regulated in addition to p21cip1 at both mRNA and protein levels. We also confirmed up-regulation of the Notch ligand Jagged-1 mRNA and protein in 5637 following Musashi1 depletion. The finding that several proteins involved in Notch signalling are affected by Musashi1 may provide one explanation why we did not observe a full-scale effect of MSI1 knockdown on Notch signalling, e.g. induction of only HEY1, but not HES1, among the prototypic Notch target genes. There are moreover indications that Notch signalling in urothelial carcinomas may be generally defective, as Notch proteins may be down-regulated in this cancer type [49]. In accordance, in our study, we observed that 639v lacks Jagged-1 expression. Nevertheless, the effects on Numb, Jagged-1, HEY1 and ADAM proteases observed in the present study underline the role of Musashi1 as a regulator of Notch signalling and indicate that further studies examining the interaction of MSI1 with other Notch pathway components are warranted.

Finally, unexpectedly, a significant number of genes encoding SG components were observed to become up-regulated after MSI1 knockdown in our microarray study. We found that the formation of SGs after heat-shock treatment in 5637 cells was significantly facilitated by MSI1 depletion indicating that the high expression level of MSI1 in 5637 cells impaired the formation of SGs. In this respect, our data show striking parallels to a recent report clarifying the role of mammalian Staufen 1, a double-stranded RNA-binding protein, in the formation of SGs [50]. Like Musashi1, Staufen 1 is also recruited into SGs [13] but its high expression impaired the assembly of SGs. Moreover, depletion of Staufen 1 also led to pronounced cell death [50]. These

### Table 3 Comparison of mRNA structural parameters between the 31 most down and up-regulated mRNAs after MSI1 knockdown

| Genes status after MSI1 suppression | Mean transcript length (bps) | Mean 3'-UTR length (bps) | Mean relative length of 3'-UTR (in relation to total length) | Mean number of MSI1 binding sites per 3'-UTR | Mean number of MSI1 binding sites per relative length of 3'-UTR |
|-----------------------------------|-----------------------------|--------------------------|-------------------------------------------------------------|--------------------------------------------|-------------------------------------------------------------|
| Up-regulated                      | 3714 ± 1774                 | 1755 ± 1129              | 0.47 ± 0.21                                                 | 4 ± 3.38                                   | 8.56 ± 7.38                                                 |
| Down-regulated                    | 2043 ± 1522                 | 646 ± 872                | 0.26 ± 0.16                                                 | 0.71 ± 1.16                                | 2.31 ± 3.61                                                 |
| P-value for difference (t-test)   | 2.22 × 10⁻⁴                 | 0.75 × 10⁻⁴              | 0.55 × 10⁻⁴                                                 | 0.13 × 10⁻⁴                                | 2.20 × 10⁻⁴                                                 |

Fig. 8 Some aspects of Musashi1 function in urothelial carcinoma cells. Musashi1 is suggested to block translation of proteins involved in cell cycle and Notch signalling regulation and facilitate sequestration of the corresponding mRNAs to particles storing or degrading RNA. However, formation of SGs, which derive partly from such particles [39], under conditions of cellular stress is prohibited by Musashi1.
findings fit with earlier indications that SGs can influence apoptosis in several situations [51]. Thus, like Staufen 1, Musashi1 may not only interact with RNA processing bodies like SGs in the course of its regulating translation of specific mRNAs, but also may regulate the very formation of these bodies. Such a function could account for the broad range of mRNAs affected by MSI1 knockdown and for its overall function on cell fate, proliferation and survival.

Throughout our study, we observed remarkable differences in the response to Musashi1 knockdown between the two bladder cancer cell lines 5637 and 639v (e.g. Figs 4, 5 and 7), despite their very similar initial levels of MSI1 and efficiencies of Musashi1 knockdown (cf. Figs 1A and 2). It is unlikely that the differences are caused by Musashi2 compensating, as MSI2 expression is lower in 639v than in 5637 (Fig. 1B) and the percentage increase after MSI1-siRNA treatment was similar. This increase in MSI2 and other changes, including a pronounced increase in HEY1 expression, illustrate that Musashi1 knockdown did elicit certain effects in 639v, although these did not result in major changes of apoptosis or cell-cycle distribution. A known difference between the cell lines that may influence their propensity towards apoptosis is the overexpression of E2F3 in 5637, due to a gene amplification [52], in comparison to 639v. In any case, the difference between the cell lines highlights again the cell-context specific action of Musashi1. Obviously, the ultimate effect of a translational regulator depends strongly on whether its mRNA targets are transcribed at all. The example of Jagged-1 (Fig. 5B) which is not expressed in 639v illustrates this argument. More generally, it is tempting to speculate that the weaker effects of Musashi1 in 639v cells may be related to the inability of these cells to form SGs. Conceivably, one or more essential factors required for their assembly may differ between 5637 and 639v. The cell pair, which otherwise shares many typical genetic defects of invasive bladder cancers, may therefore provide a good experimental system to identify factors cooperating with and regulating Musashi1 function and SG formation.

An important open question emerging from our study is to which extent Musashi1 expression may contribute to bladder cancer development. The bladder cancer cell lines used contain typical genetic and epigenetic aberrations of invasive urothelial cancers. A subset of them expressed, whereas others lacked MSI1 mRNA. We have accordingly observed a wide variation of MSI1 mRNA expression in bladder cancer tissue samples (Nikpour et al., unpublished data). This suggests that Musashi1 may also be relevant for survival and growth of selected urothelial cancers in the patients. Given the potential link of Musashi1 to stem cell function, a future assessment of the importance of Musashi1 in vivo will most of all require the identification of the cell types within the urothelial tumours that express the protein.

In summary, our results support the idea that MSI1 functions as a regulator of cell proliferation and apoptosis in certain cancer cells. Our data confirm that regulators of the cell cycle and of Notch signalling are regulated by Musashi1. Furthermore, our data suggest that a much larger set of mRNAs are Musashi1 targets, and that the protein may regulate not only their translation, but also their turnover. In these functions, mutual interactions with RNA processing microorganelles, such as SGs, appear to be highly relevant.

Acknowledgements

We thank Dr. Nicolas Stoecklein for kindly providing the Numb antibody and primers. P.N. was supported partially by the Christiane and Claudia Hempel-Stiftung. C.S. is supported by FastTrack (Robert Bosch Foundation) and EuTRACC (Integrated Project, grant no. LSHG-CT-2007-037445).

Conflict of interest

The authors confirm that there are no conflicts of interest.

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Fig. S1 Analysis of MSI1 methylation. Bisulphite sequencing of the MSI1 promoter region in selected cell lines and two independent urothelial cell cultures (NUECs). The localization of the 55 investigated CpG sites relative to the transcriptional start site is indicated on top; the black arrows represent location and direction of the bisulphite sequencing primers. Black and white cycles denote methylated and unmethylated CpG sites, respectively. The signs in parentheses indicate corresponding relative mRNA expression levels: [-] no or low expression and [++] high expression.

Table S1 Sequences of primers for real-time RT-PCR

Table S2 Genes up-regulated or down-regulated after MSI1 knockdown according to microarray analysis

Please note: Wiley-Blackwell are not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.
References

1. Okano H, Imai T, Okabe M. Musashi: a translational regulator of cell fate. J Cell Sci. 2002; 115: 1355–9.
2. Okano H, Kawahara H, Toriya M, et al. Function of RNA-binding protein Musashi-1 in stem cells. Exp Cell Res. 2005; 306: 349–56.
3. Good P, Yoda A, Sakakibara S, et al. The human Musashi homolog 1 (MSI1) gene encoding the homologue of Musashi/Nrp-1, a neural RNA-binding protein putatively expressed in CNS stem cells and neuronal progenitor cells. Genomics. 1998; 52: 382–4.

Sakakibara S, Nakamura Y, Satoh H, et al. RNA-binding protein Musashi2: developmentally regulated expression in neural precursor cells and subpopulations of neurons in mammalian CNS. J Neurosci. 2001; 21: 8091–107.

5. Kayahara T, Sawada M, Takaishi S, et al. Candidate markers for stem and early progenitor cells, Musashi-1 and Hes1, are expressed in crypt base columnar cells of mouse small intestine. FEBS Lett. 2003; 535: 131–5.

6. Potten CS, Booth C, Tudor GL, et al. Identification of a putative intestinal stem cell and early lineage marker; musashi-1. Differentiation. 2003; 71: 28–41.

7. Akasaka Y, Saikawa Y, Fujita K, et al. Expression of a candidate marker for progenitor cells, Musashi-1, in the proliferative regions of human antrum and its decreased expression in intestinal metaplasia. Histopathology. 2005; 47: 348–56.

8. Clarke RB, Sponce K, Anderson E, et al. A putative human breast stem cell population is enriched for steroid receptor-positive cells. Dev Biol. 2005; 277: 443–56.

9. Sugiyama-Nakagiri Y, Akimya M, Shibata S, et al. Expression of RNA-binding protein Musashi in hair follicle development and hair cycle progression. Am J Pathol. 2006; 168: 80–92.

10. Imai T, Tokunaga A, Yoshida T, et al. The neural RNA-binding protein Musashi1 translationally regulates mammalian numb gene expression by interacting with its mRNA. Mol Cell Biol. 2001; 21: 3888–900.

11. Battelli C, Nikopoulos GN, Mitchell JG, et al. The RNA-binding protein Musashi-1 regulates neural development through the translational repression of p21(WAF1). Mol Cell Neurosci. 2006; 31: 85–96.

12. Erhardt JA, Pittman RN. Ectopic p21(WAF1) expression induces differentiation-specific cell cycle changes in PC12 cells characteristic of nerve growth factor treatment. J Biol Chem. 1998; 273: 23517–23.

13. Kawahara H, Imai T, Imataka H, et al. Neural RNA-binding protein Musashi1 inhibits translation initiation by competing with eIF4G for PABP. J Cell Biol. 2008; 181: 639–53.

14. Hemmati HD, Nakano I, Lazareff JA, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Nat Acad Sci USA. 2003; 100: 15179–83.

15. Seigal GM, Hackam AS, Ganguly A, et al. Human embryonic and neuronal stem cell markers in retinoblastoma. Mol Vis. 2007; 13: 823–32.

16. Gottle M, Wolf M, Staebler A, et al. Increased expression of the adult stem cell marker Musashi-1 in endometriosis and endometrial carcinoma. J Pathol. 2008; 215: 317–29.

17. Sureban SM, May R, George RJ, et al. Knockdown of RNA binding protein Musashi1 leads to tumor regression in vivo. Gastroenterology. 2008; 134: 1445–58.

18. Nakano A, Kanemura Y, Mori K, et al. Expression of the Neural RNA-binding protein Musashi1 in pediatric brain tumors. Pediatr Neurosurg. 2007; 43: 799–84.

19. Toda M, Iizuka Y, Yu W, et al. Expression of the neural RNA-binding protein Musashi1 in human gliomas. Glia. 2001; 34: 1–7.

20. Shu HJ, Saito T, Watanabe H, et al. Expression of the Musashi1 gene encoding the RNA-binding protein in human hepatoma cell lines. Biochem Biophys Res Commun. 2002; 293: 150–4.

21. Swiatkowski S, Seillert HH, Steinhoff C, et al. Activities of MAP–kinase pathways in normal uroepithelial cells and urothelial carcinoma cell lines. Exp Cell Res. 2003; 282: 48–57.

22. Hoffmann MA, Muller M, Engers R, et al. Epigenetic control of CTCLF/BORIS and OCT4 expression in urogenital malignancies. Biochem Pharmacol. 2006; 72: 1577–88.

23. Janssen K, Pohlmann S, Janicke RU, et al. Apaf-1 and caspase-9 deficiency prevents apoptosis in a Bax-controlled pathway and promotes clonogenic survival during paclitaxel treatment. Blood. 2007; 110: 3662–72.

24. Kenzelmann M, Klaren R, Hergenhahn M, et al. High-accuracy amplification of nanogram total RNA amounts for gene profiling. Genomics. 2004; 83: 550–8.

25. Ihaka R, Gentleman R. R: A language for data analysis and graphics. J Comput Graph Stat. 1996; 5: 299–314.

26. Gentleman R, Carey V, Bates D, et al. Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol. 2004; 5: R80.

27. Rainer J, Sanchez-Gayo F, Stocker G, et al. CARMAweb: comprehensive R- and bioconductor-based web service for microarray data analysis. Nucl Acids Res. 2006; 34: W498–503.

28. Bolstad B, Irizarry R, Astrand M, et al. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003; 19: 185–93.

29. Tukey JW. Exploratory data analysis. Reading, MA: Addison-Wesley; 1977.

30. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc B. 1995; 57: 289–300.

31. Hofmann R, Valencia A. Implementing the ihOP concept for navigation of biomedical literature. Bioinformatics. 2005; 21: i252–8.

32. Zheng B, Kirov S, Snoddy J. WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucl Acids Res. 2005; 33: W741–8.

33. Chen G, Cizeau J, Vande Velde C, et al. Nix and Nip3 form a subfamily of pro-apoptotic mitochondrial proteins. J Biol Chem. 1999; 274: 7–10.

34. LaVoie MJ, Selkoe DJ. The Notch ligands, Jagged and Delta, are sequentially processed by alpha-secretase and presenilin/gamma-secretase and release signaling fragments. J Biol Chem. 2003; 278: 34427–37.

35. Dickinson LA, Edgar AJ, Ehley J, et al. Cyclin L is an RS domain protein involved in pre-mRNA splicing. J Biol Chem. 2002; 277: 25465–73.

36. Wozniak MA, Kwong L, Chodniewicz D, et al. R-Ras controls membrane protrusion and cell migration through the spatial regulation of Rac and Rho. Mol Biol Cell. 2005; 16: 84–96.

37. Ma S, Huang J. Regularized gene selection in cancer microarray meta-analysis. BMC Bioinformatics. 2009. doi:10.1186/1471-2105-10-1.

38. Yamasaki S, Stoecklin G, Kedersha N, et al. T-cell intracellular antigen-1 (TIA-1)-induced translational silencing promotes...
the decay of selected mRNAs. *J Biol Chem.* 2007; 282: 30070–7.
39. Anderson P, Kedersha N. Stress granules: the Tao of RNA triage. *Trends Biochem Sci.* 2008; 33: 141–50.
40. MacNicol AM, Wilczynska A, MacNicol MC. Function and regulation of the mammalian Musashi mRNA translational regulator. *Biochem Soc Trans.* 2008; 36: 528–30.
41. Dobson NR, Zhou YX, Flint NC, et al. Musashi1 RNA-binding protein regulates oligodendrocyte lineage cell differentiation and survival. *Glia.* 2008; 56: 318–30.
42. Siddall NA, McLaughlin EA, Marriner NL, et al. The RNA-binding protein Musashi is required intrinsically to maintain stem cell identity. *Proc Nat Acad Sci USA.* 2006; 103: 8402–7.
43. Wang XY, Yin Y, Yuan H, et al. Musashi1 modulates mammary progenitor cell expansion through proliferin-mediated activation of the Wnt and Notch pathways. *Mol Cell Biol.* 2008; 28: 3589–99.
44. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. *Mol Cancer Therapeutics.* 2002; 1: 639–49.
45. Philipp-Staheli J, Payne SR, Kemp CJ. p27(Kip1): regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. *Exp Cell Res.* 2001; 264: 148–68.
46. King KL, Cidlowski JA. Cell cycle and apoptosis: common pathways to life and death. *J Cell Biochem.* 1995; 58: 175–80.
47. Meikrantz W, Schlegel R. Apoptosis and the cell cycle. *J Cell Biochem.* 1995; 58: 160–74.
48. Meikrantz W, Gisselbrecht S, Tam SW, et al. Activation of cyclin A-dependent protein kinases during apoptosis. *Proc Nat Acad Sci USA.* 1994; 91: 3754–8.
49. Shi TP, Xu H, Wei JF, et al. Association of low expression of notch-1 and jagged-1 in human papillary bladder cancer and shorter survival. *J Urol.* 2008; 180: 361–6.
50. Thomas MG, Martinez Tosar LJ, Desbats MA, et al. Mammalian Staufen 1 is recruited to stress granules and impairs their assembly. *J Cell Sci.* 2009; 122: 563–73.
51. Arimoto K, Fukuda H, Imajoh-Ohmi S, Saito H, et al. Formation of stress granules inhibits apoptosis by suppressing stress-responsive MAPK pathways. *Nature Cell Biol.* 2008; 10: 1324–32.
52. Wu Q, Hoffmann MJ, Hartmann FH, et al. Amplification and overexpression of the ID4 gene at 6p22.3 in bladder cancer. *BMC Mol Cancer.* 2005. doi:10.1186/1476-4598-4-16.